•Bifidobacterium Breve SHMB 8001 Alleviates DSS-Induced Colitis in Mice Via Modulating the Intestinal Barrier and Gut Microbiota
•HLA Class II Alleles Are Associated With Anti-Drug Antibodies in Ulcerative Colitis Patients Treated With Etrolizumab
•Redrawing the gut map: evolving probiotic approaches to microbiota modulation in inflammatory bowel disease
•Identification of key bioactive compounds of medicine-food homologous substances and their multi-target intervention effects in ulcerative colitis treatment
•Rebalancing the inflammatory trajectory from inflammatory bowel disease to colitis-associated colorectal cancer via artemisinin-based multitarget therapy
